Cargando…
Impact of pegloticase on patient outcomes in refractory gout: current perspectives
Gout is currently the most frequent cause of inflammatory arthritis worldwide and is responsible for poor health-related quality of life and loss of work productivity. It is caused by high levels of serum urate, leading to the deposition of monosodium urate crystals in joints and soft tissues. This...
Autores principales: | Cunha, Rita N, Aguiar, Renata, Farinha, Filipa |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6201997/ https://www.ncbi.nlm.nih.gov/pubmed/30425593 http://dx.doi.org/10.2147/OARRR.S176951 |
Ejemplares similares
-
Pegloticase in Uncontrolled Gout: The Infusion Nurse Perspective
por: Baxter, Britni, et al.
Publicado: (2023) -
New advances in the treatment of gout: review of pegloticase
por: Reinders, Mattheus K, et al.
Publicado: (2010) -
Critical appraisal of the role of pegloticase in the management of gout
por: Ea, Hang-Korng, et al.
Publicado: (2012) -
Long-term safety of pegloticase in chronic gout refractory to conventional treatment
por: Becker, Michael A, et al.
Publicado: (2013) -
A Case Report of Successful Management of Refractory Polyarticular Gout With Pegloticase
por: Alnabwani, Dina, et al.
Publicado: (2022)